Aytu Biopharma (AYTU) Short term Debt (2011 - 2026)

Aytu Biopharma (AYTU) has 15 years of Short term Debt data on file, last reported at $1.9 million in Q1 2026.

• On a quarterly basis, Short term Debt changed 0.0% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $9.1 million, up 278.41% from the prior year.
• Short term Debt for Q1 2026 stood at $1.9 million, down from $9.1 million in the prior quarter.
• Over the last five years, Short term Debt for AYTU reached as high as $9.1 million in Q4 2025 and fell as low as $62000.0 in Q3 2023.
• Historically, Short term Debt has averaged $3.1 million across 5 years, with a median of $1.9 million in 2024.
• Across the five-year window, Short term Debt slumped 99.23% in 2023 and soared 6787.1% in 2024, its largest moves.
• Year by year, Short term Debt stood at $90000.0 in 2022, then jumped by 1040.0% to $1.0 million in 2023, then jumped by 80.99% to $1.9 million in 2024, then jumped by 388.69% to $9.1 million in 2025, then plunged by 79.54% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $1.9 million in Q1 2026, $9.1 million in Q4 2025, and $1.9 million in Q3 2025.